Want to see VRDN full AI Analyst Report?
Viridian Therapeutics (VRDN) AI Stock Analysis
Top Page
Viridian Therapeutics
(NASDAQ:VRDN)
The score is held back primarily by weak financial performance—large ongoing losses and substantial cash burn—despite improved revenue and a still-solid balance sheet. Technical indicators are moderately positive in the near-to-mid term, and corporate events (capital raise, debt repayment, and manufacturing agreement) improve flexibility and execution readiness, but valuation remains constrained by negative earnings and no dividend.
Viridian Therapeutics (VRDN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.79B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.81M
- Price to Earnings (P/E)
- -7.0
- Beta (1Y)
- 0.64
- Revenue Growth
- 23220.33%
- EPS Growth
- 13.06%
- Country
- US
- Employees
- 252
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Viridian Therapeutics Business Overview & Revenue Model
Company Description
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through...
How the Company Makes Money
Viridian Therapeutics is a clinical-stage company and, based on publicly available information, does not have an approved commercial product generating recurring product sales; therefore, its ongoing operations have primarily been funded through capi...
Viridian Therapeutics Earnings Call Summary
The earnings call reflects significant progress and positive developments in the company's pipeline, particularly with the completion of enrollment in the THRIVE trial, a strong financial position, and positive regulatory interactions. However, there are challenges, such as the extended timeline for BLA submission and concerns about hearing impairment assessments in clinical trials.
Q1-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During Viridian Therapeutics' Q1 2024 earnings call, the company provided several updates on their pipeline and financial outlook. Viridian announced the completion of enrollment for their THRIVE Phase III trial for the 001 IV program, surpassing the target with 113 patients. They anticipate top-line results in September 2024 and plan a BLA submission for the 001 program in the second half of 2025. The company also highlighted progress in their FcRn portfolio, with an IND for 006 expected by the end of 2024 and 008 nonhuman primate data anticipated in the second half of 2024. Viridian ended the quarter with $613 million in cash, cash equivalents, and short-term investments, maintaining a cash runway into the second half of 2026.
Viridian Therapeutics Financial Statement Overview
Summary
Revenue has stepped up meaningfully (TTM 2026 ~$71M) with strong gross profit, but profitability and cash generation are major weaknesses: TTM 2026 net income is a large loss (~-$387M) and operating/free cash flow are deeply negative (OCF ~-$333M; FCF ~-$335M). The balance sheet is supportive with sizable equity (~$662M) and low leverage (debt-to-equity ~0.08), though losses and rising debt levels remain a concern.
Income Statement
24NegativeBalance Sheet
63PositiveCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 71.13M | 70.85M | 302.00K | 314.00K | 1.77M | 2.96M |
| Gross Profit | 70.81M | 70.85M | 302.00K | 314.00K | 1.77M | 2.96M |
| EBITDA | -367.57M | -337.19M | -266.36M | -235.37M | -129.13M | -79.29M |
| Net Income | -386.97M | -342.60M | -269.95M | -237.73M | -129.87M | -79.41M |
Balance Sheet | ||||||
| Total Assets | 1.10B | 899.42M | 742.40M | 490.42M | 435.09M | 203.71M |
| Cash, Cash Equivalents and Short-Term Investments | 981.53M | 874.65M | 717.58M | 477.37M | 424.55M | 196.97M |
| Total Debt | 242.88M | 50.69M | 21.09M | 21.05M | 5.26M | 1.04M |
| Total Liabilities | 435.14M | 177.25M | 70.76M | 48.40M | 40.03M | 15.99M |
| Stockholders Equity | 662.10M | 722.17M | 671.64M | 442.02M | 395.06M | 187.72M |
Cash Flow | ||||||
| Free Cash Flow | -335.04M | -276.89M | -232.83M | -185.07M | -94.64M | -54.92M |
| Operating Cash Flow | -333.34M | -276.39M | -232.32M | -184.17M | -93.84M | -54.58M |
| Investing Cash Flow | -367.24M | -37.56M | -228.65M | -94.25M | -115.13M | -74.29M |
| Financing Cash Flow | 748.24M | 426.74M | 457.74M | 225.67M | 322.24M | 125.28M |
Viridian Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRDN, the sentiment is Positive. The current price of 24.67 is above the 20-day moving average (MA) of 20.93, above the 50-day MA of 21.66, and above the 200-day MA of 21.76, indicating a bullish trend. The MACD of 1.05 indicates Negative momentum. The RSI at 69.85 is Neutral, neither overbought nor oversold. The STOCH value of 91.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VRDN.
Viridian Therapeutics Risk Analysis
Viridian Therapeutics disclosed 74 risk factors in its most recent earnings report. Viridian Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksViridian Therapeutics Peers Comparison
Overall Rating
- VRDN55Neutral
VERA53Neutral
CLDX50Neutral
ZBIO44Neutral
RARE43Neutral
MLTX39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| VRDN | 55Neutral | $2.79B | -6.99 | -61.35% | ― | 23220.33% | 13.06% |
| VERA | 53Neutral | $2.23B | -5.29 | -84.13% | ― | ― | -63.94% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CLDX | 50Neutral | $2.36B | -6.90 | -52.36% | ― | -97.27% | -44.90% |
| ZBIO | 44Neutral | $1.85B | -2.95 | -189.68% | ― | -93.33% | -127.13% |
| RARE | 43Neutral | $1.59B | -2.76 | 392.35% | ― | 17.50% | -5.66% |
| MLTX | 39Underperform | $1.00B | -3.06 | -82.68% | ― | ― | -37.48% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VRDN | Viridian Therapeutics, Inc. | 24.67 | 1.52 | 6.57% | |
| CLDX | Celldex Therapeutics | 30.10 | 5.35 | 21.62% | |
| RARE | Ultragenyx Pharmaceutical, Inc. | 16.10 | -17.37 | -51.90% | |
| MLTX | Moonlake Immunotherapeutics | 11.78 | 1.58 | 15.49% | |
| VERA | Vera Therapeutics, Inc. | 30.98 | 5.04 | 19.43% | |
| ZBIO | Zenas BioPharma, Inc. | 28.39 | -2.94 | -9.38% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026